ArticleJournal of gynecologic oncology2026
The effectiveness of a 3-dimensional printed vaginal dilator in mitigating radiation-induced vaginal stenosis for patients with cervical cancer.
Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveVaginal stenosis (VS) is a common adverse effect of pelvic radiotherapy. Current guidelines recommend vaginal dilation to maintain tissue elasticity and prevent VS. Previously, patients were instructed to self-dilate using own fingers. The current study assessed the effectiveness of using a 3-dimensional (3D) printed vaginal dilator (VD) for mitigating vaginal narrowing and shortening in cervical cancer patients within 1 year after radiotherapy.
methodsVDs were developed and validated by radiation therapists using a 3D printer. We enrolled 67 female patients diagnosed with cervical cancer at Chulabhorn Hospital to test the dilators. As a baseline, vaginal diameter and length were measured using the dilator before intracavitary radiotherapy. The patients were instructed on the use of VDs and provided with information guides and logbooks. Physical examinations were conducted at intervals of 1, 3, 6, 9, and 12 months post-radiotherapy.
resultsThe patients' average age was 51.75 years (standard deviation=13.23). 57% of all patients were diagnosed with stage III squamous cell carcinoma, and 66% underwent concurrent chemoradiation therapy. With the use of dilators, patients exhibited shortened and narrowed vaginal canals at 9 months and 1 month after receiving radiotherapy treatment. Most patients went on to develop VS. However, in most cases patients exhibited grade 1 VS according to the Late Effects in Normal Tissues-Subjective, Objective, Management and Analytic classification, with only 15.79% of patients exhibiting grade 2 VS.
conclusionThe use of a VD could potentially lessen the severity of VS induced by radiotherapy/brachytherapy.
trial registrationThai Clinical Trial Registry Identifier: TCTR20250309001.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.